piR-63,076 knockdown attenuated the development of pulmonary hypertension by inhibiting the proliferation of PASMCs, implicating its potential role as a biomarker and a therapeutic target for pulmonary hypertension [136]. Here, PIR is linked to pulmonary hypertension.